Cipla partners with Eli Lilly to sell and distribute BASAGLAR insulin

Myequity news service| Date : 08-06-2018 16:30:00 IST

Cipla Limited today announced its partnership with, Eli Lilly and Company (India) Pvt. Ltd., a 100% subsidiary of Eli Lilly and Company, a global multinational pharmaceutical leader, for the marketing and distribution of Lilly’s BASAGLAR (insulin glargine injection) in India.

BASAGLAR is a long-acting insulin, given once daily to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes.

Under this agreement, Lilly’s BASAGLAR that is manufactured by Lilly, will be marketed and distributed in India by Cipla.

Luca Visini, Managing Director, Lilly India said, this strategic partnership leverages Lilly’s commitment to bring innovation to people suffering from diabetes and his company hopes to benefit from Cipla’s “strong on-ground footprint” in India.

“While insulin has been a mainstay of diabetes treatment for many years, when it comes to initiating basal insulin therapy, people with diabetes still face several emotional and practical challenges,” he said.

Cipla expects to start selling BASAGLAR in India by end of the year 2018.

Cipla shares closed at Rs. 559.65 up 3.50%.


More from Myequity